Tags

Type your tag names separated by a space and hit enter

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation.
Eur J Pharmacol. 2004 Nov 28; 505(1-3):195-203.EJ

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a nuclear hormone receptor super family that has recently been implicated in atherosclerosis, inflammation, cancer, infertility, and demyelination. Oxidative stress, neutrophil infiltration, proinflammatory cytokines, and the exhibition of luminal acid play a role in the pathogenesis of gastric injury induced by ischemia-reperfusion. Rosiglitazone, a specific PPAR-gamma ligand, has been shown to have antiinflammatory activity, but its effects on experimental ischemia-reperfusion gastric injury remain unknown. We have investigated the effects of the rosiglitazone on gastric injury caused by ischemia following reperfusion in rats. Tumour necrosis factor-alpha (TNF-alpha) levels and changes in enzymatic activities of myeloperoxidase, as a marker of neutrophils infiltration, xanthine oxidase, superoxide dismutase, and glutathione peroxidase, were determined. Histological analysis of the lesions was also carried out. Pretreatment with 1 or 4 mg/kg of rosiglitazone ameliorated the gastric damage induced by clamping the celiac artery for 30 min followed by 60 min of reperfusion. It significantly (P<0.05) reduced the index of neutrophil infiltration and the levels of the cytokine. Rosiglitazone did not revert the reduced glutathione peroxidase activity but enhanced significantly (P<0.01) the decreased xanthine oxidase and superoxide dismutase activities in gastric mucosa of ischemic rats. In conclusion, rosiglitazone reduces the damage in ischemia-reperfusion gastric injury and alleviates the inflammatory response and the oxidative events.

Authors+Show Affiliations

Department of Pharmacology, Faculty of Pharmacy, University of Sevilla, Professor García González Street, 41012 Seville, Spain.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15556153

Citation

Villegas, Isabel, et al. "Rosiglitazone, an Agonist of Peroxisome Proliferator-activated Receptor Gamma, Protects Against Gastric Ischemia-reperfusion Damage in Rats: Role of Oxygen Free Radicals Generation." European Journal of Pharmacology, vol. 505, no. 1-3, 2004, pp. 195-203.
Villegas I, Martín AR, Toma W, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol. 2004;505(1-3):195-203.
Villegas, I., Martín, A. R., Toma, W., & de la Lastra, C. A. (2004). Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. European Journal of Pharmacology, 505(1-3), 195-203.
Villegas I, et al. Rosiglitazone, an Agonist of Peroxisome Proliferator-activated Receptor Gamma, Protects Against Gastric Ischemia-reperfusion Damage in Rats: Role of Oxygen Free Radicals Generation. Eur J Pharmacol. 2004 Nov 28;505(1-3):195-203. PubMed PMID: 15556153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. AU - Villegas,Isabel, AU - Martín,Antonio Ramón, AU - Toma,Walber, AU - de la Lastra,Catalina Alarcón, PY - 2004/06/10/received PY - 2004/09/24/revised PY - 2004/10/04/accepted PY - 2004/11/24/pubmed PY - 2005/5/17/medline PY - 2004/11/24/entrez SP - 195 EP - 203 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 505 IS - 1-3 N2 - Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a nuclear hormone receptor super family that has recently been implicated in atherosclerosis, inflammation, cancer, infertility, and demyelination. Oxidative stress, neutrophil infiltration, proinflammatory cytokines, and the exhibition of luminal acid play a role in the pathogenesis of gastric injury induced by ischemia-reperfusion. Rosiglitazone, a specific PPAR-gamma ligand, has been shown to have antiinflammatory activity, but its effects on experimental ischemia-reperfusion gastric injury remain unknown. We have investigated the effects of the rosiglitazone on gastric injury caused by ischemia following reperfusion in rats. Tumour necrosis factor-alpha (TNF-alpha) levels and changes in enzymatic activities of myeloperoxidase, as a marker of neutrophils infiltration, xanthine oxidase, superoxide dismutase, and glutathione peroxidase, were determined. Histological analysis of the lesions was also carried out. Pretreatment with 1 or 4 mg/kg of rosiglitazone ameliorated the gastric damage induced by clamping the celiac artery for 30 min followed by 60 min of reperfusion. It significantly (P<0.05) reduced the index of neutrophil infiltration and the levels of the cytokine. Rosiglitazone did not revert the reduced glutathione peroxidase activity but enhanced significantly (P<0.01) the decreased xanthine oxidase and superoxide dismutase activities in gastric mucosa of ischemic rats. In conclusion, rosiglitazone reduces the damage in ischemia-reperfusion gastric injury and alleviates the inflammatory response and the oxidative events. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/15556153/Rosiglitazone_an_agonist_of_peroxisome_proliferator_activated_receptor_gamma_protects_against_gastric_ischemia_reperfusion_damage_in_rats:_role_of_oxygen_free_radicals_generation_ DB - PRIME DP - Unbound Medicine ER -